HARROW, INC.
HROW evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for HROW—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · HROW
Harrow, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic products, with a portfolio that includes branded drugs like IHEEZO and VERKAZIA, and a pipeline candidate MELT-300.
Key risk: High debt burden
BioSniper Score
Based on 6 of 6 signals
Market Cap
$1.40B
Cash Runway
39.2 moLead Asset
surf-100 (Preclinical)
Next Catalyst
Patent_Expiry · Aug 3, 2028Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 3 clinical trials · 6 catalysts for HARROW, INC..
Harrow, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic products, with a portfolio that includes branded drugs like IHEEZO and VERKAZIA, and a pipeline candidate MELT-300.
- Cash and equivalents of $83.9M as of 2026-06-30 [sec].
- Total revenue of $70.7M for the six months ended 2026-06-30 [sec].
- Net loss of $17.3M for the six months ended 2026-06-30 [sec].
- Total debt of $292.4M as of 2026-06-30 [sec].
- Shareholders' equity of $52.4M as of 2026-06-30 [sec].
What works
- Cash position of $83.9M as of 2026-06-30 provides near-term liquidity to fund operations [sec].
- Portfolio includes multiple approved ophthalmic products (e.g., IHEEZO, VERKAZIA, TOBRADEX ST) with patent protection extending into the 2030s [sec_mda].
- Revenue of $70.7M in the first half of 2026 indicates commercial traction [sec].
What to weigh
- Net loss of $17.3M in the first half of 2026 reflects ongoing operating losses [sec].
- Total debt of $292.4M as of 2026-06-30 represents a significant leverage burden [sec].
- R&D expenses increased to $5.9M in Q1 2026 from $3.0M in Q1 2025, driven by clinical trials for the MELT-300 candidate [sec_mda].
- The company faces risks related to FDA compliance at its New Jersey outsourcing facility [sec_mda].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“Our cash on hand at June 30, 2026 was $83,889,000 compared to $72,927,000 at December 31, 2025.”
SEC MD&A · August 10, 2026
R&D expense increase due to MELT-300 clinical trials
“The increase in R&D expenses of $2,869,000 in the three months ended March 31, 2026 as compared”
SEC MD&A · May 11, 2026
Catalyst timeline
- 2028-08-03 · Patent/Exclusivity Expiry: TOBRADEX ST — Expiration of patent/exclusivity for TOBRADEX ST could open the market to generic competition.
- 2029-06-02 · Patent/Exclusivity Expiry: VERKAZIA — Expiration of patent/exclusivity for VERKAZIA may reduce product exclusivity.
- 2032-03-31 · Patent/Exclusivity Expiry: ILEVRO — Expiration of patent/exclusivity for ILEVRO could impact revenue.
- 2032-07-09 · Patent/Exclusivity Expiry: ZERVIATE — Expiration of patent/exclusivity for ZERVIATE may allow generic entry.
- 2036-05-09 · Patent/Exclusivity Expiry: BYQLOVI — Expiration of patent/exclusivity for BYQLOVI could affect long-term revenue.
- 2039-05-14 · Patent/Exclusivity Expiry: IHEEZO — Expiration of patent/exclusivity for IHEEZO, a key product, may eventually face competition.
Risks & what to watch (4)›
Key risks
- High debt burden — Total debt of $292.4M as of 2026-06-30 may constrain financial flexibility [sec].
- Operating losses continue — Net loss of $17.3M in H1 2026 indicates ongoing cash burn [sec].
- FDA compliance risk — Ongoing communications with FDA regarding compliance at New Jersey facility [sec_mda].
- MELT-300 development risk — R&D expenses rising due to clinical trials; no assurance of FDA approval [sec_mda].
What to watch
- Progress of MELT-300 clinical trials and any FDA submission milestones [sec_mda].
- Ability to manage debt maturities and refinancing plans [sec_mda].
- FDA resolution regarding compliance at the New Jersey outsourcing facility [sec_mda].
- Revenue growth trajectory from approved ophthalmic products [sec].
Sources: SEC filings · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run HARROW, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available HARROW, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
39.2 months
D/E 26.45 · 0% dilution
Lead: Preclinical
1 candidate
6 upcoming, next in ~704d
4 buys · 5 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for HARROW, INC.?
Harrow, Inc. is a pharmaceutical company focused on developing and commercializing ophthalmic products, with a portfolio that includes branded drugs like IHEEZO and VERKAZIA, and a pipeline candidate MELT-300.
What is HARROW, INC.'s lead drug candidate?
HARROW, INC.'s most advanced tracked candidate is surf-100 (Preclinical) for ocular surface related indications.
What is HARROW, INC.'s next catalyst?
HARROW, INC.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: TOBRADEX ST" — expected August 3, 2028.
Who is the CEO of HARROW, INC.?
Mr. Mark L. Baum J.D. is the chief executive officer of HARROW, INC. (HROW).
Where is HARROW, INC. headquartered?
HARROW, INC. (HROW) is headquartered in Nashville, TN, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.